Highly active antiretroviral therapy and beta-chemokines

Clinical and Experimental Immunology

Volumn 130, Issue 2, 2002, Pages 169-171

  Brichacek, B ^a,b   Bukrinsky, M ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; ANTIBODY; ANTIRETROVIRUS AGENT; BETA CHEMOKINE; CD4 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CX3C CHEMOKINE; GAMMA CHEMOKINE; INDINAVIR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; RITONAVIR; SAQUINAVIR; STROMAL CELL DERIVED FACTOR 1; VIRUS RNA;

BLOOD; CELL ACTIVATION; CELL CLONE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG TARGETING; GENE MUTATION; HEMOPHILIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 6; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR BINDING; REVIEW; T LYMPHOCYTE; TARGET CELL; VACCINATION; VIROGENESIS; VIRUS ISOLATION; VIRUS LOAD; VIRUS STRAIN;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHEMOKINES, CC; HIV INFECTIONS; HIV-1; HUMANS;

EID: 0036406487     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.02010.x     Document Type: Review

References (34)

1. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18:217-42.
2. + T cells. Science 1995; 270:1811-15.
3. Choe H, Farzan M, Sun Y et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85:1135-48.
4. Doranz BJ, Rucker J, Yi Y et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85:1149-58.
5. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-73.
6. Deng H, Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-6.
7. Alkhatib G, Combadiere C, Broder CC et al. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-8.
8. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272:872-7.
9. Huang Y, Paxton WA, Wolinsky SM et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2:1240-3.
10. Paxton WA, Martin SR, Tse D et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996; 2:412-17.
11. Zagury D, Lachgar A, Chams V et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 1998; 95:3857-61.
12. +, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. J Virol 1998; 72:876-81.
13. Scala E, D'Offizi G, Rosso R et al. C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol 1997; 158:4485-92.
14. + T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci USA 2000; 97:13812-7.
15. Garzino-Demo A, Moss RB, Margolick JB et al. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA 1999; 96:11986-91.
16. + cells in HIV infection produce macrophage inflammatory protein-1 alpha and RANTES: A comparative study in long-term survivors and progressor patients. Immunol Lett 1996; 53:105-8.
17. Polo S, Veglia F, Malnati MS et al. Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. AIDS 1999; 13:447-54.
18. Bisset LR, Rothen M, Joller-Jemelka HI, Dubs RW, Grob PJ, Opravil M. Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. AIDS 1997; 11:485-91.
19. Aukrust P, Muller F, Froland SS. Circulating levels of RANTES in human immunodeficiency virus type 1 infection: Effect of potent anti-retroviral therapy. J Infect Dis 1998; 177:1091-6.
20. Kumar D, Parato K, Kumar A, Sun E, Cameron DW, Angel JB. Sustained suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1alpha and MIP-1beta. AIDS Res Hum Retroviruses 1999; 15:1073-7.
21. Fransen S, Copeland KF, Smieja M, Smaill F, Rosenthal KL. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent anti-retroviral therapy predict sustained suppression of viral replication. J Infect Dis 2000; 181:505-12.
22. Plana M, Garcia F, Gallart T et al. Immunological benefits of anti-retroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 2000; 14:1921-33.
23. Carter LM, Peters BS, Ellis BA, Wolstencroft RA. Highly active anti-retroviral therapy normalizes the potential for MIP-1alpha production in HIV infection. J Infect 2000; 41:252-5.
24. Sanchez-Carrasquillo E, Garcia V, Rivera CE, Febo I, Melendez-Guerrero LM. CCR5 and beta-chemokines in HIV-1 infected children. PR Health Sci J 2000; 19:345-51.
25. Giovannetti A, Ensoli F, Mazzetta F et al. CCR5 and CXCR4 chemokine receptor expression and beta-chemokine production during early T cell repopulation induced by highly active anti-retroviral therapy. Clin Exp Immunol 1999; 118:87-94.
26. Blanco J, Cabrera C, Jou A, Ruiz L, Clotet B, Este JA. Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. AIDS 1999; 13:547-55.
27. Pierdominici M, Giovannetti A, Ensoli F et al. Changes in CCR5 and CXCR4 expression and beta-chemokine production in HIV-1-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29:122-31.
28. Gebhard JR, Perry CM, Harkins S et al. Coxsackievirus B3-induced myocarditis: Perforin exacerbates disease, but plays no detectable role in virus clearance. Am J Pathol 1998; 153:417-28.
29. Burton CT, Hardy GAD, Sullivan AK et al. Impact of NNRT1 compared to PI-based highly active antiretroviral therapy on CCR5 receptor expression, β-chemokines and IL-16 secretion in HIV-1 expression. Clin Exp Immunol 2002; 301:286-92.
30. Kinter A, Catanzaro A, Monaco J et al. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4 (+) T cells: Role of signal transduction. Proc Natl Acad Sci USA 1998; 95:11880-5.
31. Cheng-Mayer C, Seto D, Tateno M, Levy JA. Biologic features of HIV-1 that correlate with virulence in the host. Science 1988; 240:80-2.
32. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185:621-8.
33. Grivel JC, Ito Y, Faga G et al. Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nat Med 2001; 7:1232-5.
34. Lusso P, Gallo RC. Human herpesvirus 6 in AIDS. Immunol Today 1995; 16:67-71.